Results 201 to 210 of about 635,186 (354)

TRIM47 Regulates Energy Metabolism via Glycolytic Reprogramming to Drive Hepatocellular Carcinoma Progression and Represents an Efficient Therapeutic Target

open access: yesAdvanced Science, EarlyView.
This study identifies TRIM47 as a key driver of liver cancer progression by promoting glycolysis through ubiquitin‐mediated degradation of the gluconeogenic enzyme FBP1. TRIM47 enhances glucose uptake, lactate and ATP production, and tumor growth and metastasis.
Weijie Sun   +17 more
wiley   +1 more source

Liver Stiffness Directs Intrahepatic Cholesterol Accumulation Through YAP/TAZ in Metabolic Dysfunction‐Associated Steatotic Liver Disease

open access: yesAdvanced Science, EarlyView.
Liver stiffness promotes intrahepatic cholesterol accumulation by repressing LXRα through YAP/TAZ activation. Stiff matrices impair cholesterol efflux in hepatocytes, while YAP/TAZ deletion restores LXRα activity and prevents cholesterol‐induced fibrosis.
Na Young Lee   +9 more
wiley   +1 more source

Mitochondrial Calcium Uniporter Drives Chemoresistance in Pancreatic Cancer via Glutathione‐Mediated Stemness Maintenance

open access: yesAdvanced Science, EarlyView.
PDAC has a poor prognosis due to chemoresistance. We revealed that MCU upregulation is associated with chemoresistance and stemness in PDAC. MCU‐mediated Ca2+ influx induced ER stress, activating the PERK‐ATF4/NRF2 axis to enhance PSAT1/SLC711 expression and glutathione synthesis, reducing ROS and maintaining stemness.
Zekun Li   +17 more
wiley   +1 more source

Tendon Organoids Enable Functional Tendon Rejuvenation Through ALKBH5‐Dependent RNA Demethylation

open access: yesAdvanced Science, EarlyView.
FT organoids reverse the aged phenotype of tendon cells, reinstating a fetal‐like state. This breakthrough establishes a potent cell source for tendon tissue engineering, effectively advancing regenerative medicine. ABSTRACT Adult tendon injuries pose a major clinical challenge due to limited self‐repair capacity, resulting in suboptimal regeneration ...
Tian Qin   +14 more
wiley   +1 more source

Anti‐PD‐1 Nanobody‐Armored MSLN CAR‐T Therapy for Malignant Mesothelioma: Preclinical and Clinical Studies

open access: yesAdvanced Science, EarlyView.
A novel therapy using engineered immune cells (NAC‐T cells) showed promise for refractory malignant mesothelioma. Based on the encouraging preclinical data, the first‐in‐human trial is initiated, demonstrating tolerable safety and promising anti‐tumor activity (ORR 63.6%, DCR 100%, including one CR).
Yan Sun   +23 more
wiley   +1 more source

Home - About - Disclaimer - Privacy